

COMPUTED TOMOGRAPHY (CT)

CONSULTATION REQUEST

<u>Guidelines</u> : Regio	onal Inpatient? Yes	I No □			
Healthcare Provider to complete requisition. Incomplete					
requisitions will be returned. 2. Fax requisitions to Diagnostic Imaging Central Intake: 1-855-461-3493					
If there is relevant prior imaging from outside facilities, please provide reports with requisition.					
Is the patient hearing im	paired? Yes □	No □			
Does patient require an i Mobility Needs?	interpreter? Yes □ Yes □	No □ No □			
CT Exam Requested	 Please be specific 				
☐ Thorax ☐ Hea	•	Spine			
☐ Abdomen ☐ Sin		Spine			
☐ Pelvis ☐ Ned		pine			
☐ Renal Colic ☐ Fac					
☐ CT Angio					
□ Other					
Clinical Information					
Cililical illiorillation					
-					
☐ Cancer Staging and	d/or Diagnosis				
☐ Cancer Staging and☐ Other	d/or Diagnosis				
		Where			
□ Other Relevant Previous Treatmen □ Previous Chemothen	nts/Studies Date	Where			
□ Other Relevant Previous Treatment □ Previous Chemothent □ Previous Radiothera	nts/Studies Date rapy	Where			
□ Other Relevant Previous Treatmen □ Previous Chemothen	nts/Studies Date rapy apy Imaging)	Where			
□ Other Relevant Previous Treatmer □ Previous Chemother □ Previous Radiothera □ MRI (Magnetic Resonance I □ CT (Computed Tomography) □ Ultrasound	nts/Studies Date rapy apy Imaging)	Where			
□ Other Relevant Previous Treatment □ Previous Chemothent □ Previous Radiotherat □ MRI (Magnetic Resonance Iou CT (Computed Tomography) □ Ultrasound □ X-Ray	nts/Studies Date rapy apy Imaging)	Where			
□ Other Relevant Previous Treatmer □ Previous Chemother □ Previous Radiothera □ MRI (Magnetic Resonance I □ CT (Computed Tomography) □ Ultrasound	nts/Studies Date rapy apy Imaging)	Where			
□ Other Relevant Previous Treatment Previous Chemothent Previous Radiotherate MRI (Magnetic Resonance It CT (Computed Tomography) Ultrasound X-Ray Nuclear Medicine	nts/Studies Date rapy apy lmaging)	Where			
□ Other Relevant Previous Treatment Previous Chemothent Previous Radiotherate MRI (Magnetic Resonance I CT (Computed Tomography) Ultrasound X-Ray Nuclear Medicine Angiography	nts/Studies Date rapy apy lmaging))	Where			
□ Other Relevant Previous Treatment Previous Chemothent Previous Radiotherate MRI (Magnetic Resonance I CT (Computed Tomography) Ultrasound X-Ray Nuclear Medicine Angiography Priority (P) Assessment	nts/Studies Date rapy appy Imaging)) ent	Where			
□ Other Relevant Previous Treatment Previous Chemothent Previous Radiotherate MRI (Magnetic Resonance I CT (Computed Tomography) Ultrasound X-Ray Nuclear Medicine Angiography	nts/Studies Date rapy Apy Imaging) ent gent apatient/Urgent	Where			
□ Other Relevant Previous Treatment Previous Chemothent Previous Radiothera MRI (Magnetic Resonance I CT (Computed Tomography) Ultrasound X-Ray Nuclear Medicine Angiography Priority (P) Assessment P1 -Immediate - Emerging P2 -Within 48 Hours-In	ent spent sp	Where			
□ Other Relevant Previous Treatment Previous Chemothent Previous Radiotherate MRI (Magnetic Resonance I CT (Computed Tomography) Ultrasound X-Ray Nuclear Medicine Angiography Priority (P) Assessment P1 -Immediate - Emerging P2 -Within 48 Hours-Interpretation P3 -Within 10 Days - Statement P4 - Within 10 Days - Statement	ent gent patient/Urgent Semi-Urgent Non-Urgent	Where			
Relevant Previous Treatment Previous Chemother Previous Radiothera MRI (Magnetic Resonance I CT (Computed Tomography) Ultrasound X-Ray Nuclear Medicine Angiography Priority (P) Assessment P1 -Immediate - Emerging P2 -Within 48 Hours-In P3 -Within 10 Days - S P4 -Within 4 Weeks - N Greater than 4 Weeks	ent gent patient/Urgent Semi-Urgent Non-Urgent	Where			
Relevant Previous Treatment Previous Chemother Previous Radiothera MRI (Magnetic Resonance I CT (Computed Tomography) Ultrasound X-Ray Nuclear Medicine Angiography Priority (P) Assessment P1 -Immediate - Emerging P2 -Within 48 Hours-In P3 -Within 10 Days - S P4 -Within 4 Weeks - N Greater than 4 Weeks	ent spent specify Date				
□ Other Relevant Previous Treatment Previous Chemothent Previous Radiothera MRI (Magnetic Resonance I CT (Computed Tomography) Ultrasound X-Ray Nuclear Medicine Angiography Priority (P) Assessment P1 -Immediate - Emerging P2 -Within 48 Hours-Interpretation P3 -Within 10 Days - Store P4 -Within 4 Weeks - Nthe Computed Referring Site or Clinic Referring Site or Cli	ent spent spent spent spent spent-Urgent speni-Urgent specify Date				
□ Other Relevant Previous Treatment Previous Chemothent Previous Radiothera MRI (Magnetic Resonance I CT (Computed Tomography) Ultrasound X-Ray Nuclear Medicine Angiography Priority (P) Assessment P1 -Immediate - Emerging P2 -Within 48 Hours-Interpretation P3 -Within 10 Days - State P4 -Within 4 Weeks - Note P4 -Within 4 Weeks - Not	ent spent spent spent spent spent spent spent spent spent specify Date specify Date				

Patient Name:	
D.O.B. (YYYY-MM-DD):	
Address:	
City/Town, Prov:	
Postal Code:	Tel:
Health Card #:	Version:
Telephone: ()	
Alternate: ()	

CENTRAL INTAKE (FOR P2-P4	PRIORITY)
Is the patient willing to travel for the shortest we Yes No Which site is the patient willing to have their appoint	
Dryden Regional Health Centre Fort Frances Riverside Healthcare	
Kenora Lake of the Woods District Hospital	
Sioux Lookout Meno Ya Win Health Centre	
Thunder Bay Regional Health Sciences Centre	

Guidance screening:				
Kidney problems or transplant?	□ Yes □ No			
Waiting to see a kidney specialist or urologist?	☐ Yes ☐ No			
If yes to the above, an eGFR evaluation must be performed prior to iodinated contrast exam.				
eGFR (estimated Glomerular Filtration Rate)				
Date of blood test(Please specify if pending)				
Is patient on dialysis?	☐ Yes ☐ No			
(See reverse side for Guidelines on Contrast Associated Acute Kidney Injury)				
Allergies				
Allergy to IV contrast media containing iodine?				
Will patient be pre-medicated?	☐ Yes ☐ No			
Allergy to medications? • Please list	☐ Yes ☐ No			
- I lease list				
Other severe allergies				
(0)				
(See protocol on reverse side).				

GUIDELINES ON CONTRAST ASSOCIATED ACUTE KIDNEY INJURY

(Adapted from the 2022 Canadian Association of Radiologists - Webpage: https://car.ca/patient-care/practice-guidelines and 2023 American College of Radiology – Webpage: https://www.acr.org/Clinical-Resources/Contrast-Manual)

CONTRAST ASSOCIATED ACUTE KIDNEY INJURY (CA-AKI) is defined as an increase in creatinine $>26 \mu mol/L$ (or 50%) in 48 hours, following an IV contrast procedure. The most important predictors of CA-AKI are the presence of CKD, or AKI from other causes.

FOR PATIENTS WITH 1 OR MORE RISK FACTORS for impaired renal function, an eGFR (estimated Glomerular Filtration Rate) will be required within three (3) months prior to an intravenous contrast CT examination.

ALL PATIENTS with eGFR >30 ml/min/1.73 m ²	PATIENTS with eGFR less than 30 ml/min/1.73 m ²	
Proceed with indicated contrast imaging study	Individual patient decision to explain and balance the risks of CA-AKI against the risks and uncertainties or delayed or suboptimal imaging. There is a lack of evidence on benefit of volume expansion; institutions may choose practices best suited to their local environments.	
Hold nephrotoxic drugs 48 hours prior to contrast when possible. (Nephrotoxic Drugs include: loop diuretics, amphotericin B, aminoglycosides, vancomycin, non-steroidal anti-inflammatory drugs, cancer and immune suppressant chemotherapy) Vascular disease: hypertension, congestive heart disease, cardiac or peripheral vascular disease Collagen Vascular Disease: a heterogeneous group of autoimmune disorders of unknown etiology. They include systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), progressive systemic sclerosis (PSS), scleroderma (SD), dermatomyositis (DM)/polymyositis (PM), ankylosing spondylitis (AS), Sjögren syndrome (SS), and mixed connective-tissue disease (MCTD).		
Hold diuretics especially Furosemide at least 24 hours prior to contrast, when possible.		
Do not recommend restricting medically indicated repeat contrast doses in lower risk patients (eGFR >30, no AKI, IV route)		

EVALUATION OF FOLLOW-UP RENAL FUNCTION TESTS IS THE RESPONSIBILITY OF THE ORDERING PHYSICIAN.

METFORMIN PROTOCOL:

Patients with eGFR \leq 30 mL/min/1.73 m² or AKI, metformin should be held at the time of, or prior to, ICM administration, and should not be restarted for at least 48 hours and only then if kidney function remains stable (<25% increase compared with baseline creatinine) and the ongoing use of metformin has been re-assessed by the patient's clinical team.

CONTRAST MEDIA ALLERGY PREMEDICATION (See Guidelines: https://www.acr.org/Clinical-Resources/Contrast-Manual)

- Prednisone 50 milligrams orally, thirteen (13), seven (7) and one (1) hour prior to study
- Diphenhydramine (Benadryl) 50 milligrams orally one (1) hour prior to study

BREASTFEEDING PATIENTS

Because of the very small percentage of iodinated contrast medium that is excreted into the breast milk and absorbed by the infant's gut, we believe that the available data suggest that it is safe for the mother and infant to continue breast-feeding after receiving such an agent. Ultimately, an informed decision to temporarily stop breast-feeding should be left up to the mother after these facts are communicated. If the mother remains concerned about any potential ill effects to the infant, she may abstain from breast-feeding from the time of contrast administration for a period of 12 to 24 hours. There is no value to stop breast-feeding beyond 24 hours. The mother should be told to express and discard breast milk from both breasts during that period. In anticipation of this, she may wish to use a breast pump to obtain milk before the contrast-enhanced study to feed the infant during the 24-hour period following the examination.

<u>Abbreviation Legend</u>: INR – International Normalized Ratio m²- metre squared

PTT – Partial Thromboplastin Time **kg** – kilogram

ml – milliliter h – hour min – minute meq – milliequivalent

CA-AKI – Contrast Associated Acute Kidney Injury